Amgen

Amgen is a global biopharma company whose current cash engine is a broad marketed portfolio, while its healthspan-relevant option is MariTide (maridebart cafraglutide/AMG 133), a long-acting obesity and metabolic-disease asset. The healthspan thesis is that Amgen is trying to convert chronic obesity care from frequent injections into a lower-burden maintenance platform.

Amgen is already a very large, profitable payer of R&D: FY2025 revenue $36.75B, Q2 2026 revenue $10.05B, Q2 2026 non-GAAP operating margin 48.4% per the earnings release, and Q2 2026 GAAP operating margin ~34.9% from companyfacts-derived operating income / revenue. The company generated $3.5B of free cash flow in Q2 2026 and ended the quarter with $14.0B cash against $57.3B debt. MariTide is still pre-revenue, so this is an option-value story funded by an existing cash machine.

Amgen is a global biopharma whose healthspan-relevant bet is MariTide (maridebart cafraglutide / AMG 133), a long-acting antibody-peptide conjugate that activates GLP-1 and antagonizes GIPR, positioned as a lower-frequency maintenance platform for obesity and cardiometabolic disease. The base business (immunology, oncology, bone, CV) funds the obesity option.

• monetization model: Product sales (biologics/small molecules) plus license/collaboration/other revenue; no subscription/SaaS. (Amgen FY2024 10-K, Business & Note 2 Revenue, sec.gov , Acc. No. 0000318154-25-000010.)
• revenue mix: One operating segment; product sales ~95% of total revenues, other ~5%. Top product sales: Prolia ~13%, Enbrel ~10%, Repatha ~7%, Otezla ~7%, Xgeva ~6%, Tepezza ~6%; balance other products/biosimilars. (same 10-K, Note 2 Revenue.)
• who pays: Direct buyers are wholesalers/distributors; economic burden falls on third-party payers (commercial, Medicare/Medicaid) and providers/hospitals/clinics that prescribe/administer. (same 10-K, Business & Risk Factors.)
• margin_value_capture: Value accrues in product sales; GAAP gross margin ~72%, GAAP operating margin ~25% after R&D, SG&A, amortization. (same 10-K, Consolidated Statements of Income.)

• customer classes: Payers & Insurers, Health Systems & Providers, Pharma & Biotech (collaboration/licensing); direct wholesale/distribution channel. (same 10-K, Business & Note 2 Revenue.)

Amgen reports as a human-therapeutics business. The cleanest filed revenue split is product sales vs. other revenues:

Primary source:

SEC EDGAR, Amgen Inc., Form 10-K for fiscal year ended December 31, 2023, filed 2024-02-13, CIK 0000318154, accession 0000318154-24-000012, URL: sec.gov (accessed 2026-04-26).

Cross-verification for total revenue:

SEC EDGAR, Amgen Inc., Form 8-K filed 2024-02-06, Exhibit 99.1 Q4/FY2023 earnings release, URL: sec.gov (accessed 2026-04-26). The 8-K also reports full-year 2023 total revenues of $28,190 million.

Top-three product revenue from Amgen’s 10-K product table:

Each individual product figure is [SINGLE-SOURCE] from the Amgen 10-K FY2023 product revenue table; I did not have a second independent source that separately breaks out the same product-level number.

Formula:

\[

\text{Top-3 concentration} = \frac{\text{Prolia} + \text{Enbrel} + \text{Otezla}}{\text{Total product sales}}

\]

Inputs from Amgen 10-K FY2023:

\[

\frac{4,009 + 3,697 + 2,188}{26,910} = \frac{9,894}{26,910} = 36.8\%

\]

Sensitivity:

Interpretation: concentration risk is moderate. Even the largest product, Prolia, is only about 14.9% of product sales [SINGLE-SOURCE], and Enbrel’s decline can be partially absorbed unless multiple large products decline simultaneously.

Net margin is directly calculable from two Amgen filings:

\[

\text{Net margin} = \frac{\$6,717\ \text{million}}{\$28,190\ \text{million}} = 23.8\%

\]

Primary sources:

Amgen 10-K FY2023; Amgen 8-K Q4/FY2023 earnings release.

Gross margin and operating margin: needs primary source validation. I did not live-verify the cost-of-sales and operating-expense line items to a standard I would want to cite. Use the Consolidated Statements of Operations in the Amgen 10-K FY2023 for the authoritative gross and operating line items.

Amgen makes money from prescription human therapeutics. Revenue is recognized when product is sold to distributors/wholesalers, hospitals, pharmacies, and other direct purchasers. Reported product sales are net of gross-to-net adjustments including rebates, discounts, chargebacks, and government-mandated discounts.

Source: Amgen 10-K FY2023, Item 1 and Item 7 discussion of revenue recognition, pricing, and gross-to-net adjustments.

Ultimate payers are patients, commercial health plans, Medicare, Medicaid, and other government programs. Amgen’s direct customers are mainly U.S. wholesale distributors.

Amgen’s 10-K names the major U.S. wholesale distributors:

• McKesson Corporation
• Cencora, Inc. (formerly AmerisourceBergen Corporation)
• Cardinal Health, Inc.

The exact percentage concentration attributable to these three customers requires exact reading from the 10-K customer-concentration disclosure and is left as needs primary source validation. The qualitative fact that they are the main direct U.S. distributor customers is from Amgen 10-K FY2023.

From the Amgen 10-K, the direct commercial chain is:

1. U.S. wholesale distributors — McKesson, Cencora, Cardinal Health are named; they buy and distribute most U.S. product volume.
2. Hospitals, oncology clinics, infusion centers, dialysis centers, retail/specialty pharmacies — purchase through distributors or directly.
3. Commercial and government payers — reimburse but are not usually the direct purchaser in the distribution chain.
4. Patients — ultimate users.

The three named distributors are the closest thing Amgen’s filing identifies as major direct customers. Exact revenue concentration per distributor is needs primary source validation.

Amgen operates as one reportable segment — human therapeutics [S1]. The 10-K does not break reportable revenue into separate operating segments by market or geography; therefore product-level revenue is the most decision-useful decomposition. The business model is research, development, manufacturing, and commercialization of biologics and small molecules, with revenue recognized mainly when product is sold to wholesalers, distributors, hospitals, and pharmacies.

Using the FY2023 10-K product-sales table, total revenues were $28,190 million, product sales were $26,910 million, and other revenues were $1,280 million [S1]. Product-level shares below are calculated against total revenues.

The 10-K’s business and risk-factor discussion identifies these customer classes [S1]:

• Wholesalers/distributors: McKesson Corporation, AmerisourceBergen Corporation, and Cardinal Health, Inc. These are large-volume channel customers; concentration creates counterparty and credit exposure.
• Specialty distributors and specialty pharmacies — relevant for high-cost, cold-chain, or REMS-restricted products.
• Hospitals and infusion centers — especially for oncology, nephrology, and hospital-administered biologics.
• Dialysis providers and nephrology clinics — relevant for Aranesp and related supportive-care products.
• Rheumatology, dermatology, endocrinology, and bone-health practices — relevant for Enbrel, Otezla, Prolia, Evenity, Repatha.
• Government and commercial payers — Medicare, Medicaid, and private insurers are the reimbursement counterparties, not direct customers but decisive for demand.

From the product labels and approved indications [S4][S5][S6][S7], the buyer/patient archetypes include:

• Postmenopausal women with osteoporosis at high fracture risk
• Patients with bone metastases from solid tumors
• Patients with rheumatoid arthritis, plaque psoriasis, or psoriatic arthritis
• Patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia
• Patients with multiple myeloma
• Patients with chemotherapy-induced neutropenia or chronic immune thrombocytopenia

These are high-medical-need chronic or serious disease populations, which supports relatively inelastic unit demand but high political and payer scrutiny on price.

FY2025 revenue was $36.75B, with gross profit of $24.71B and operating income of $9.08B, implying FY2025 gross margin ~67.3% and operating margin ~24.7% (SEC 10-K / companyfacts). Q2 2026 revenue was $10.05B (+9.5% YoY vs. $9.18B in Q2 2025), with gross profit of $7.24B and operating income of $3.51B, implying Q2 gross margin ~72.1% and GAAP operating margin ~34.9% (SEC 10-Q / companyfacts). The Q2 2026 release also showed $14.0B cash and $57.3B debt outstanding.

Q2 2026 revenue was $10.054B (+9.5% YoY), R&D expense $1.868B, and operating income $3.514B (SEC 10-Q, companyfacts, ended 2026-06-30). FY2025 revenue was $36.751B with operating income $9.080B, net income $7.711B, and R&D of $7.272B (SEC 10-K, companyfacts, ended 2025-12-31).

The bottleneck is not the GLP-1 target (LLY/NVO already own it) — it is whether a long-PK antibody-peptide conjugate can deliver durable efficacy at a fraction of the weekly dosing burden, and whether Amgen's biologic manufacturing scale can support a competitive obesity launch.

The claimed maintenance burden is 4-6 doses/year. Versus a weekly injectable benchmark (52 doses/year), that is an 88.5% to 92.3% reduction in administration events; even the monthly start phase (12 doses/year) cuts injection events by 76.9%. That is the economic lever: if a lower-burden schedule improves persistence, Amgen can win chronic-treatment share; if phase 3 forces more frequent titration or discontinuation, MariTide loses its main edge.

1. R&D intensity — the annual toll to defend the moat. FY2025 R&D of $7.272B against $36.751B revenue = 19.8% of revenue. Q2 2026 held the same shape ($1.868B / $10.054B = 18.6%). This is the recurring cost of defending and replacing biologic franchises before patent expiry — over a typical ~10-year franchise life, that is roughly $70B+ of cumulative R&D per decade.

1. Free-cash-flow bridge. FY2025 FCF = OCF $9.958B − capex $1.858B = $8.100B (22.0% FCF margin). H1 2026 FCF = $6.191B − $1.225B = $4.966B. Amgen's obesity option is fully self-funded by the base business.

1. Dose-frequency economics (formalized). Weekly incretin baseline = 52 doses/year. MariTide monthly-start phase = 12 doses/year (−76.9% administration events); maintenance phase = 4–6 doses/year (−88.5% to −92.3%). The economic claim is persistence: if fewer injections reduce non-adherence and discontinuation, Amgen wins chronic-treatment share on a convenience vector rather than raw efficacy.

1. Net debt / balance-sheet capacity. Total debt = $54.604B LT + $4.599B current = $59.20B; net debt = $59.20B − $9.129B cash = $50.07B (10-K FY2025 companyfacts). The obesity launch (commercial build + manufacturing) is funded on a leveraged balance sheet — a reminder that the option is bought with debt, not surplus cash.

1. NNT to prevent one cardiovascular death. Circulation mortality table: evolocumab arm 156 CV deaths (2.8% 5-yr KM rate) vs placebo 195 (3.6%). Absolute risk reduction ≈ 3.6% − 2.8% = 0.8pp over ~5 yrs → NNT ≈ 125 patients treated ~5 years to prevent one CV death. The economic translation: a mortality claim is the clinical-data moat — it took 15 years, 51 trials and >57,000 patients (Amgen PR) to establish, and no rival can copy it without running its own ~12,000-patient, ~4.6-yr outcomes trial.

1. Franchise run-rate vs the indication-expansion lever. Repatha Q2 2026 $953M × 4 ≈ $3.8B annualized (+37% YoY). The primary-prevention population (high-risk ASCVD/diabetes without a prior event) is multiples larger than the legacy secondary-prevention base; at the current growth pace Repatha approaches $5B+ run-rate by 2028, climbing from ~9% of total revenue toward a double-digit share.

1. Cost-of-moat vs moat-defended. Amgen's cardiometabolic CVOT reinvestment (FOURIER 2017 → VESALIUS-CV 2026 → EVOLVE-MI ongoing) is the toll that buys the exclusive mortality label. The defended base is the ~$3.8B Repatha franchise and its patent runway into the 2030s — a multi-hundred-million-dollar-per-trial spend defending a multi-billion franchise.

1. Competitive asymmetry. Regeneron/Sanofi's Praluent (ODYSSEY OUTCOMES) has a secondary-prevention signal but NO primary-prevention all-cause-mortality claim; Novartis's Leqvio (inclisiran, siRNA) competes on biannual dosing but lacks a comparable mortality dataset. Repatha's "first and only" mortality label is durable until a rival completes its own equivalent outcomes trial.

No direct contradiction with Amgen was found. The two filings reinforce the same structural reality:

• AbbVie reports Humira revenues falling sharply due to U.S. biosimilar competition.
• Amgen reports a diversified portfolio where newer products such as Prolia, EVENITY, Repatha, Otezla, KRYSTEXXA, and TEPEZZA partially offset legacy erosion.
• Amgen is a biosimilar supplier, including AMGEVITA, which benefits from Humira biosimilar entry.

The only tension worth flagging is framing: AbbVie emphasizes Skyrizi/Rinvoq growth as the offset to Humira erosion. Amgen frames its growth around multiple products including Prolia, EVENITY, Repatha, Otezla, and rare-disease products from Horizon. That difference is strategic positioning, not contradictory financial disclosure.

This is a portfolio-level unit-economics approximation from Tier-1 product-level data. It is not a per-patient unit calculation; Amgen’s 10-K does not disclose enough per-product unit volume and net price to compute a clean per-patient unit economic without mixing external assumptions.